Floatz logo

ibi376

Indolent Non-hodgkin Lymphoma

Chinese PLA General HospitalPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

39 Active assets in the Indolent Non-hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
Pembrolizumab
University of Washington
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase 3BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →